Advances in gene-targeted therapies together with the approval of Moderna’s and Pfizer’s RNA-based COVID 19 vaccines are revolutionizing the future of healthcare. These transformative medications rely on novel nanoparticle vehicles which can safely and effectively deliver them to target cells and organs.Barcode Nanotech’s Tag&Track technology enables the generation and identification of new RNA carriers that lead these new drugs to their designated target cell. As the enabler of new drugs through targeted delivery, the company is collaborating with some of the largest pharma companies in the world to develop new medications.

Now, the company aims to develop a wholly owned RNA therapy (RNA medication and delivery vehicle). The Ross team will conduct a market-assessment to identify the optimal penetration strategy in one selected indication. The project includes generating a strategy for the formation of a new US-based pharma startup.